Sanofi R&D chief urges Western pharma to rethink China sourcing

· Health · France · China

Sanofi's new research and development chief said Western drugmakers cannot ignore China's accelerating innovation and need to reconsider how the country's rise as a global biopharma powerhouse changes the way they source new medicines. The comments reflect a broader shift in the industry, as Chinese biotechs have moved from producing generics to generating novel compounds that multinationals increasingly license or acquire. For Western companies, that raises strategic questions about whether to compete with, partner with or buy from Chinese labs, and how to structure deals amid geopolitical tension and regulatory scrutiny of cross-border transactions. The remarks from a senior executive at one of Europe's largest drugmakers give weight to the view that China is now a primary source of early-stage pipeline assets rather than a low-cost manufacturing base alone.

Why it matters：China's biotech sector is becoming a primary source of new drug candidates, forcing global pharma to weigh licensing and M&A there against geopolitical and regulatory risk.

Key points

  • Sanofi's new R&D chief said Western drugmakers cannot ignore China's innovation.
  • The comments concern how companies source new medicines from China.
  • Chinese biotechs are increasingly a source of novel compounds for licensing and acquisition.

Sources (original reporting)

More stories from this day